CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed
Drug / intervention
genistein +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00000613
NCT00000613Phase 2Completed
CompareCT.gov

CVD Risk and Health in Postmenopausal Phytoestrogen Users

National Heart, Lung, and Blood Institute (NHLBI)·interventional·Posted Oct 28, 1999·Updated Feb 29, 2016

In Brief

A Phase 2 clinical trial evaluating dietary supplements, genistein, and 1 other intervention for Bone Diseases and 7 related conditions. Completed.

Detailed Summary

To determine the acceptability and benefits of use of a dietary supplement of the phytoestrogen, genistein, versus placebo on heart disease risk factors, bone density, and psychosocial outcomes in postmenopausal women.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBone Diseases, Cardiovascular Diseases, Coronary Disease, Depression, Heart Diseases, Myocardial Ischemia, Osteoporosis, Postmenopause
Countries--
Collaborators--

Timeline

Phase 2CompletedFinished
1997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 28, 1999
Enrollment StartApr 1, 1997
Study CompletionDec 1, 2004
TodayJul 2, 2026
Posted 26.7 years ago

Interventions

dietary supplementsbehavioral

genisteindrug

diet, soy proteinsbehavioral